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Objectives: To describe whether body mass index (BMI) is a clinically meaningful predictor of patient
reported outcomes following primary total hip replacement (THR) surgery.
Design: Combined data from prospective cohort studies. We obtained information from four cohorts of
patients receiving primary THR for osteoarthritis: Exeter Primary Outcomes Study (EPOS) (n ¼ 1431);
EUROHIP (n ¼ 1327); Elective Orthopaedic Centre (n ¼ 2832); and St. Helier (n ¼ 787). The exposure of
interest was pre-operative BMI. Confounding variables included: age, sex, SF-36 mental health, comor-
bidities, ﬁxed ﬂexion, analgesic use, college education, OA in other joints, expectation of less pain,
radiographic K&L grade, ASA grade, years of hip pain. The primary outcome was the Oxford Hip Score
(OHS). Regression models describe the association of BMI on outcome adjusting for all confounders.
Results: For a 5-unit increase in BMI, the attained 12-monthOHSdecreases by 0.78 points 95%CI (0.27e1.28),
P-value 0.001. Compared to people of normal BMI (20e25), those in the obese class II (BMI 35e40) would
have a 12-month OHS that is 2.34 points lower. Although statistically signiﬁcant this effect is small and not
clinicallymeaningful in contrast to the substantial change inOHS seenacross all BMI groupings. In obese class
II patients achieved a 22.2 point change in OHS following surgery.
Conclusions: Patients achieved substantial change in OHS after THR across all BMI categories, which
greatly outweighs the small difference in attained post-operative score. The ﬁndings suggest BMI should
not present a barrier to access THR in terms of PROMs.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.A. Judge, NIHR Musculoskel-
Orthopaedics, Rheumatology
Windmill Road, Headington,
-0-1865-227-966.
k (A. Judge), rajbir.batra@
ms.ox.ac.uk (G.E. Thomas),
javaid@ndorms.ox.ac.uk (M.
rray), p.dieppe@exeter.ac.uk
. Dreinhoefer), klaus-peter.
er), richard.ﬁeld@eoc.nhs.uk
.arden@ndorms.ox.ac.uk (N.
s Research Society International. PIntroduction
Total hip replacement surgery (THR) is a commonly performed
and successful surgical intervention, providing substantial relief
frompain and improvement in functional disability in patients with
hip arthritis1e3. The lifetime risk for undergoing a hip replacement
in the UK is estimated to be 11.6% for women and 7.1% for men4.
Recent studies have reported that around 10% of patients are not
satisﬁed with their hip replacement within a year following sur-
gery5e8. It is generally acknowledged that the key indications for
surgery include joint pain, functional limitation and radiographic
evidence of arthritis9. There is no consensus as to the severity ofublished by Elsevier Ltd. All rights reserved.
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accepted criteria to determine the indications for surgery9.
Obesity is a known risk factor for the development of hip
osteoarthritis11, and it has been shown that obese patients have a
greater clinical need for surgery12. Data from the UK National Joint
Registry13 show that the average body mass index (BMI) of patients
receiving hip replacement has been increasing steadily over time.
Contrary to this, there is growing evidence in the UK that com-
missioners are restricting access to hip replacement for obese pa-
tients stating that obesity increases the risk of complications
following surgery14e25. Accordingly NICE clinical guidelines have
stated that restriction of referral for surgery based on health issues
such as BMI has no basis in evidence and that whilst the risks of
complications may be slightly higher there is no evidence sup-
porting this as a reason to deny treatment26. Regarding patient
reported outcomes, literature on the effect of BMI is conﬂicting.
Some authors conclude that obesity is associated with worse pain
and functional outcomes27e29, whilst others have found no asso-
ciation18,30e34. Literature reviews conclude that observed differ-
ences in risk for obese patients are small, and they can still expect
large symptomatic improvement following surgery35. There are
several limitations within the existing literature: the sample sizes
of some studies are small with few patients in the morbidly obese
groups; statistical methods used are weak, such as categorising BMI
reducing statistical power and selection bias due to missing data;
and most importantly limited adjustment for confounding.
To our knowledge, data from a single cohort study does not exist
containing the required information to adjust for all important
confounding variables, and multiple data sources are therefore
necessary. Within the recent literature methodology has been
developed in order to combine data from multiple sources in order
to adjust for awider range of confounding factors36 or allow awider
range of variables to be included in a model37.
Set against the conﬂicting literature regarding the inﬂuence of
obesity on patient reported outcomes following hip replacement,
and concerns that access to surgery is being restricted for obese
patients, as part of the Clinical Outcomes in Arthoplasty Study
(COASt) the aim of this paper was to provide a comprehensive
assessment of the effect of obesity on patient reported outcomes of
hip replacement, through combining data from large prospective
cohort studies allowing us to take account of a wide and compre-
hensive range of important confounding factors.
Methods
As part of the COASt study access was available to data from four
large prospective cohorts of patients receiving primary hip
replacement (THR) for osteoarthritis. The datasets have previously
been reported elsewhere and are described in brief as follows: (1)
The European collaborative database of cost and practice patterns of
THR (EUROHIP) contains information on 1327 patients receiving
primary THR across 20 European orthopaedic centres in 12 coun-
tries in 200238; (2) Exeter Primary Outcomes Study (EPOS) is a pro-
spective study of 1431 patients with a primary diagnosis of OAwho
had THR between 1999 and 200239; (3) Elective Orthopaedic Centre
database (EOC) e a purpose built Orthopaedic treatment centre
opened in 2004 performing THR for four acute NHS Trusts in South
West London, UK. The EOC database includes 2832 patients
receiving primary THR for OA between 2005 and 20087,40; (4) St.
Helier Hospital outcome programme e a district general hospital
serving the London Boroughs of Sutton and Merton5. The dataset
contains 787 patients with OA receiving primary THR whose op-
erations were undertaken from 1995 to 2007.
The primary outcome of interest is the Oxford Hip Score (OHS)41,
consisting of 12 questions asking patients to describe their hip painand function during the past 4 weeks. Each question is on a Likert
scale taking values from 0 to 4. The total score is created by sum-
ming the responses to each of the 12 questions, ranging from 0 to
48, where 0 is the worst possible score (most severe symptoms)
and 48 the best score (least symptoms). Follow up OHS question-
naires were collected at 12-months in all four studies. However, in
the EOC and EUROHIP cohorts the 12-month OHS was only
collected for a minority of patients. The predominant follow up for
EOC was the 6-month OHS, and for the EUROHIP study the 12-
month WOMAC score. We therefore derived a 12-month OHS for
both of these studies in the followingway: (1) EOCe 250 patients in
the EOC and St. Helier datasets completed both 6 and 12-month
OHS scores. Using truncated regression modelling we derived an
equation to predict the 12-month OHS from the 6-month OHS (R2
50.8%); (2) EUROHIP e 110 patients completed both the OHS and
WOMAC scores at baseline and 12-months follow up. Truncated
regression models were used to predict the OHS from the WOMAC
score at baseline (R2 75.5%) and 12-month follow up (R2 63.4%).
The main predictor of interest is pre-operative BMI treated as a
continuous variable. Across the cohorts data was available on a
wide range of patient and surgical variables. A-priori a list of these
variables was circulated to co-authors and consensus obtained on
the following extensive list of potential confounders: age, sex, SF-
36 mental health score, comorbidities (deep venous thrombosis,
pulmonary embolism, urinary tract infection, other musculoskel-
etal disease, neurological, respiratory, cardiovascular, renal, hepatic
disease or treatment for other medical conditions), ﬁxed ﬂexion
range of motion (degrees), analgesic use, college education, OA in
other joints, expectation of less pain, radiographic Kellgren &
Lawrence (K&L) grade, American Society of Anesthesiologists (ASA)
status, years of hip pain, surgical approach (anterolateral or pos-
terior) and femoral component offset size (millimetres offset). Each
study collected data on age, sex, BMI and Quality of Life, however
there were differences in the other confounders recorded (Table I).
Statistical methods
In accordance with Katz et al.42 we ﬁtted twomodels to describe
the association with BMI on: (1) the 12-month OHS as a measure of
the level of post-operative pain and functional status achieved by
12-months (the destination). Linear regression modelling is used
adjusting for the baseline OHS and confounding factors; (2) change
in OHS between baseline and 12-months (the journey). A repeated
measures linear regression model is ﬁtted, where the outcome is
the pre- and post-operative OHS, and an interaction term ﬁtted
between BMI and time, to describe the change in OHS over time
within BMI categories, adjusting for confounding factors.
Primary analysis
Each of the four cohort studies was analysed separately to
describe the association of BMI on outcome. Models are adjusted
only for confounders of age and sex in order to construct related
hypotheses in each study. Fixed-effects meta-analysis using inverse
variance weights is used to combine results and estimate a com-
mon effect size of BMI on outcome. We tested for evidence of
heterogeneity across studies.
Secondary analysis
As each study collected data on a different set of confounders,
combining studies together results in a high proportion of missing
data (Table I). Within the literature methodology has been devel-
oped to combine data from multiple data sources to adjust for a
wider range of variables36,37. We use the method of Multivariate
Table I
List of confounding variables available within each of the four cohort studies and distribution of the extent of missing data in each study.
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(full details of the methods are provided in a supplementary ﬁle).
We included all of the covariates (as listed earlier) together with the
outcome variable in the imputation model as this carries infor-
mation about the missing values of predictors. Regression models
were then ﬁtted to the combined dataset to describe the association
of BMI on outcome adjusting for the full range of confounding
factors.
Results
Prior to surgery baseline data was available on 6377 patients
receiving primary THR for OA, of whom 4413 (69.2%) completed
both baseline and 12-month follow up OHS and were included in
the analysis. Table II describes the characteristics of patients in each
of the four studies. There were small differences between patients
that did, and did not, complete the follow up questionnaire. Those
that completed the follow up had better pre-operative OHS in two
of the studies (EUROHIP and EOC), and in the EPOS cohort those
responding to the questionnaire were younger. Importantly, BMI
was similar in both completers and non-completers across all four
studies. For those included in the analysis, patients in the EOC
cohort had better pre-operative pain and function (as measured by
the OHS), whilst those in EUROHIP had more severe pre-operative
symptoms. Patients in the EUROHIP and St. Helier cohorts wereslightly younger than those in the other cohorts. There were a
higher proportion of men in the EUROHIP study. The distribution of
BMI was similar across all four studies (Table III) with a median of
26.8, Inter-quartile range (24.3, 30.1) and a range from 14.6 to 54.3.
Separating the distribution of BMI into WHO categories45 24 (0.9%)
of patients were underweight (BMI <18.5), 864 (31.7%) normal
(BMI 18.5e25), 1139 (41.8%) overweight (BMI 25e30), 502 (18.4%)
obese class I (BMI 30e35), 150 (5.5%) obese class II (BMI 35e40),
and 47 (1.7%) obese class III (BMI 40þ).
Primary analysis
The results of the analyses of each individual study are displayed
as a forest plot in Fig. 1. For the analysis of the effect of BMI on
attained post-operative pain and function, each of the studies
showed a small negative effect of BMI on outcome, but this did not
reach statistical signiﬁcance in all studies. The overall summary
estimate from the meta-analysis was statistically signiﬁcant sug-
gesting that after adjusting for age and sex, for a 5-unit increase in
BMI, the 12-month OHS decreases by 0.84 95%CI (0.59e1.08) points.
Secondary analysis
For the combined dataset, in the analysis of the effect of BMI on
attained post-operative pain and function, adjusting for age and sex
Table II
Descriptive statistics
Study Variables Non-completers Completers P-value*
EPOS (n ¼ 164) (n ¼ 1267)
OHS pre-op 15.81 (8.15) 16.49 (7.77) 0.46
Age at operation: 72.64 (9.93) 68.80 (9.80) <0.001
Sex:
Male 70 (43%) 462 (37%) 0.13
Female 92 (57%) 800 (63%)
BMI 26.30 (23.62, 29.76) 26.72 (24.39, 30.04) 0.21
EUROHIP (n ¼ 476) (n ¼ 851)
OHS pre-op 13.26 (8.43) 15.67 (8.61) <0.001
Age at operation: 65.68 (11.22) 65.70 (10.67) 0.98
Sex:
Male 199 (43%) 360 (45%) 0.68
Female 260 (57%) 448 (55%)
BMI 26.72 (24.02, 29.41) 26.94 (24.69, 30.12) 0.012
EOC (n ¼ 1234) (n ¼ 1598)
OHS pre-op 18.38 (8.56) 19.51 (8.77) <0.001
Age at operation: 70.27 (11.30) 70.73 (10.35) 0.27
Sex:
Male 428 (35%) 577 (36%) 0.46
Female 801 (65%) 1018 (64%)
BMI 27.34 (24.35, 30.98) 26.72 (23.89, 30.44) 0.032
ST HELIER (n ¼ 90) (n ¼ 697)
OHS pre-op 17.47 (7.63) 17.52 (8.30) 0.95
Age at operation: 66.30 (14.52) 66.54 (12.01) 0.88
Sex:
Male 37 (41%) 278 (40%)
Female 53 (59%) 419 (60%) 0.82
BMI 27.00 (23.00, 30.00) 27.00 (24.00, 30.00) 0.34
For normally distributed continuous variables numbers represent mean (standard deviation), for non-normally distributed the median (inter-quartile range).
* To compare characteristics of completers and non-completers, a chi-squared test is used for categorical variables, a two-sample t-test for normally distributed continuous
variables, and KruskaleWallis test for non-normally distributed variables.
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0.96 units 95%CI (0.57e1.35), P-value <0.001. Adjusting for all po-
tential confounding factors, the effect is attenuated to 0.78 units
95%CI (0.27e1.28), P-value 0.003. Although the effect size is small, it
is important to note that there is a cumulative linear effect where
the difference in post-op OHS becomes larger with increasing BMI.
For example, compared to people with a normal BMI (20e25),
those in obese class II (BMI 35e40) would have a post-operative
OHS that is 2.34 units lower, and those in obese class III 3.12
units lower. There was no evidence of an interaction between BMI
and the pre-operative OHS.
Repeated measures analysis exploring the change in OHS be-
tween baseline and 12-months, suggests that patients achieved
substantial improvement (change) in OHS, regardless of their pre-
operative level of BMI (Table IV). After adjusting for all con-
founders, patients in the normal group (BMI 18.5e25) had a 23.0
point change in OHS between the pre- and 12-month post-opera-
tive assessment, those in the overweight group (BMI 25e30) a 22.4
point change, the obese class I group (BMI 30e35) 22.7 points,
obese class II (BMI 35e40) 22.2 points, and obese class III (BMI 40þ)
24.2 points. Hence, there is a substantial improvement in OHS afterTable III
Distribution of BMI across the four studies
BMI categories EPOS EUROHIP EOC ST HELIER
Underweight (<18.5) 12 (1.0%) 0 (0.0%) 6 (1.8%) 6 (1.5%)
Normal (18.5e25) 370 (31.0%) 218 (27.8%) 116 (34.4%) 160 (38.8%)
Overweight (25e30) 509 (42.7%) 363 (46.3%) 123 (36.5%) 144 (35.0%)
Obese class I (30e35) 215 (18.0%) 147 (18.8%) 69 (20.5%) 71 (17.2%)
Obese class II (35e40) 70 (5.9%) 46 (5.9%) 12 (3.6%) 22 (5.3%)
Obese class III (40þ) 17 (1.4%) 10 (1.3%) 11 (3.3%) 9 (2.2%)
Cells in the table represent the number (percentage) of patients in each BMI
category.THR across all BMI categories, which greatly outweighs the small
difference in attained post-operative OHS (Fig. 2).
Discussion
Main ﬁndings
This study provides a comprehensive assessment of the asso-
ciation of BMI on PROMs of THR. Its strength lies in utilising data
from four large, representative, prospective cohort studies that
allowed us to accurately assess the size of effect of BMI on PROMs
and to adjust for a full range of potential confounders. Our ﬁndings
conﬁrm a small statistically signiﬁcant difference in the effect ofFig. 1. Results of ﬁxed-effects meta-analysis.
Table IV
Estimates of pre- and post-operative OHS from the repeated measures regression model, including an interaction of BMI with time
BMI categories Adjusting for age and sex Adjusting for all confounders
Pre-op OHS 12-month OHS Pre-op OHS 12-month OHS
Mean (95%CI) Mean (95%CI) Mean (95%CI) Mean (95%CI)
Underweight (<18.5) 14.01 (9.54e18.48) 39.31 (34.93e43.68) 14.04 (9.56e18.52) 39.34 (34.97e43.71)
Normal (18.5e25) 17.02 (15.69e18.34) 40.04 (38.72e41.36) 16.83 (15.25e18.40) 39.85 (38.25e41.45)
Overweight (25e30) 16.65 (15.38e17.91) 39.01 (37.75e40.28) 16.79 (15.22e18.36) 39.15 (37.56e40.75)
Obese class I (30e35) 14.23 (12.81e15.64) 36.95 (35.54e38.37) 14.93 (13.13e16.72) 37.66 (35.93e39.39)
Obese class II (35e40) 13.69 (11.82e15.57) 35.90 (34.01e37.79) 14.71 (12.51e16.91) 36.92 (34.72e39.11)
Obese class III (40þ) 12.25 (9.02e15.49) 36.43 (33.10e39.76) 13.66 (10.24e17.07) 37.83 (34.25e41.41)
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compared to people of normal BMI (20e25), those in the obese
class II group (BMI 35e40) would have an OHS that is 2.34 points
lower. It has previously been suggested that the minimum clinically
important difference (MCID) (the smallest amount of change in
OHS that is likely to be clinically important) is around 5 points46,
based on observations that a half standard deviation in the change
score has been shown to represent a meaningful difference47, andFig. 2. Change on OHS between baseline and 12-months follow up, stratiﬁed by BMI
categories.that the MCID may be as low as 2 points such that even a small
change may be clinically important Hence, although statistically
signiﬁcant, differences in attained 12-month OHS across different
categories of BMI only approach potential clinical relevance in
obese classes II and III. Regardless, this effect is greatly outweighed
by the substantial improvement (change) in OHS seen across all
categories of BMI (the journey) following surgery where in the
obese class II group (BMI 35e40), after adjusting for all con-
founders, patients achieved a 22.2 point change (improvement) in
OHS over the year following surgery. The ﬁndings are consistent
across studies and robust to adjustment for a wide range of con-
founding factors. The ﬁndings suggest that BMI should not present
a barrier to access THR in terms of PROMs.Strengths and limitations
The strengths of this study include the relatively large sample
size using four separate cohorts with data collected prospectively
with a good rate of follow up, the use of a reliable, valid and
responsive instrument for assessing outcomes of THR41, and the
generalizability of the ﬁndings using data from the UK and Europe.
A further strength is the comprehensive adjustment for con-
founding through combining data in a subset of the studies. A
limitation of the study is that we have only evaluated short term
outcomes at 12-months following surgery, and it is unclear what
the effect will be in the long term. In addition, only 1.6% of patients
within this study had a BMI of 40þ, hence we did not have the
power to evaluate the effect of this most severe category of obesity
on outcomes, and further work is required to determine whether
there is a threshold effect above which outcomes are worse. Across
the four studies, patients were operated on during different periods
of time and a limitation is that there are variations in the time spans
of the various cohorts. The use of multiple imputation methods
present potential limitations. They require us to make the
assumption data are missing at random (MAR), which is plausible
in the context of this study as the reason for missing data is due to
variables not being collected in the study. Plausibility is further
enhanced by inclusion of a wide range of covariates to ensure
enough variables predictive of missing information are included.
Further limitations are that in the EUROHIP study data on OHS was
only collected in a minority of patients, the majority having a
WOMAC score, hence we had to derive the OHS from the recorded
WOMAC score. Inconsistency in the outcome measures collected
across studies is not unexpectede this has lead to the development
of a core set of outcomes being supported by the COMET initiative
when collecting data for future studies48. As highlighted in a recent
systematic review49 in situations where different outcome mea-
sures have been collected it is not uncommon to map one outcome
measure to another50, as we have done in this study. Reassuringly,
the results from the EUROHIP study were entirely consistent with
those of the other three studies.
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Patient Reported Outcome Measures (PROMs) are now the fav-
oured measure of outcome used to see whether surgery has been
successful from the patient’s perspective51e53. The PROMS most
often used to assess the effects of THR include well-validated self-
assessment measures of OA severity such as the OHS41,54 or
Western Ontario and McMaster Universities (WOMAC) OA index55,
which assess pain, stiffness and function and 12-months is a
commonly used and appropriate time at which to considerwhether
surgery has been successful40. There is growing evidence in the UK
that commissioners are restricting access to hip replacement for
obese patients14e17, stating that increasing levels of obesity in-
creases the risk of complications following surgery. Within the
literature there is some evidence to support this view that obesity
increases the risk of complications, although such risks are most
consistently observed amongst the morbidly obese18e23,56. There is
evidence of an increased risk of infection amongst obese pa-
tients18,20,22,24,25,57,58, but the absolute risk is small, and this is in
keeping with existing literature across other types of surgery59e63.
An increased risk of thrombo-embolic events has recently been
observed58, again consistent with other areas of surgery63e65.
Although the risks of complications may be slightly higher in these
patients, in accordance with NICE guidelines26, there is no evidence
to support these as reasons to deny treatment. Of the studies that
have explored the effect of obesity on prosthesis survival, most
have focused on the mid term outcomes and found no difference in
survival rates22,66,67. A recent large study of longer term outcomes
over 20-years following THR found a small, but signiﬁcant, effect of
BMI with an increased risk of revision, particularly in the morbidly
obese (BMI 40þ) group, although the absolute numbers of revisions
were small68.
Regarding patient reported outcomes of hip replacement sur-
gery, evidence from the literature on the effect of BMI is conﬂicting.
Some authors conclude that increasing levels of obesity are asso-
ciated with worse pain and functional outcomes27e29, whilst others
have found no evidence of an association18,30e34. The general
consensus being that any observed differences in risk for obese
patients are small and they can still expect large symptomatic
improvement following hip replacement, even though the may not
attain the same level of post-operative pain and function35. The
main limitation of existing studies is the possibility of residual or
unmeasured confounding. Given current attempts made by com-
missioners to ration access to hip replacement on the basis of BMI,
and the conﬂicting results of existing studies, it is important to
address this and other limitations in order to strengthen the evi-
dence of whether or not a true association exists. Our ﬁndings
conﬁrm that whilst there are statistically signiﬁcant differences in
the attained level of post-operative pain and function, these dif-
ferences are not clinically relevant, and are greatly outweighed by
the substantial improvements (change) in pain and function seen
across all pre-operative categories of BMI following surgery. These
ﬁndings are robust to adjustment for an extensive range of con-
founding factors. The ﬁndings suggest that BMI should not present
a barrier to access THR in terms of PROMs.What this study adds
This study demonstrates that pre-operative levels of BMI should
not present a contra-indication for hip replacement surgery on the
basis of expected improvement in patients report pain and func-
tional outcomes. Regardless of differences in pre-operative BMI
these patients can expect to achieve substantial symptomatic
improvement following surgery. Although there are smallsigniﬁcant differences in attained post-operative scores, these dif-
ferences are small and not clinically important.Ethics
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